Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyd dengue virus serotype 3 live (attenuated) antigen
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Cyd dengue virus serotype 3 live (attenuated) antigen is a component of the tetravalent, live attenuated chimeric dengue vaccine known as CYD-TDV or Dengvaxia. This vaccine is designed to prevent infection by all four major serotypes of the dengue virus and is based on a yellow fever 17D backbone with the pre-membrane (prM) and envelope (E) genes from each respective dengue virus serotype inserted in place of those from yellow fever. The mechanism of action involves stimulating an immune response against all four types of the dengue virus, thereby providing protective immunity. The primary indication for this drug is prevention of dengue disease in individuals aged 9–45 years who have had prior infection with any type of the dengue virus[1][2][5]. It was developed by Sanofi Pasteur.
- Brand names
- Dengvaxia
- Other names
- CYD-TDVchimeric yellow fever-dengue vaccinetetravalent dengue vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on Cyd dengue virus serotype 3 live (attenuated) antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyd dengue virus serotype 3 live (attenuated) antigen.